Related Experiment Video
Updated: Aug 15, 2026
10:00
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Therapeutic role of beta-interferons in multiple sclerosis
1Department of Neurology, MC-2030, University of Chicago, 5841 South Maryland Avenue, IL 60637, USA.
Pharmacology & Therapeutics
|October 19, 2005
Summary
Interferons (IFNs) are crucial for managing multiple sclerosis (MS) by regulating immune responses. While IFNs show modest therapeutic effects in MS, incomplete immune dysfunction resolution suggests potential for improved treatments.
Area of Science:
- Neuroimmunology
- Inflammatory Diseases
- Central Nervous System (CNS) Disorders
Background:
- Multiple sclerosis (MS) is a CNS inflammatory disease driven by complex immune mechanisms.
- Interferons (IFNs) modulate innate and adaptive immunity, influencing autoimmune responses.
- While IFNs can decrease MS autoimmunity, they may exacerbate other conditions like systemic lupus erythematosus (SLE).
Purpose of the Study:
- To provide an overview of Interferons (IFNs) biological properties.
- To examine the effects of IFNs on immune cells in MS.
- To review the clinical effectiveness of IFNs in treating MS.
Main Methods:
- Review of existing literature on Interferons (IFNs) and Multiple Sclerosis (MS).
- Analysis of IFN signaling pathways and their impact on immune cell function.
- Evaluation of clinical data on IFN efficacy in MS patients.
Main Results:
- IFN signaling is complex, involving receptor binding and downstream inflammatory modulation.
- IFN treatment partially ameliorates immune dysfunction in MS patients.
- Incomplete immune resolution by IFNs contributes to their modest therapeutic effects.
Conclusions:
- IFN therapy demonstrates continued clinical efficacy in MS over time.
- Incomplete resolution of immune dysfunction suggests IFN-resistant mechanisms in MS.
- Ongoing research aims to potentiate IFN effects for enhanced MS treatment.
- IFNs remain a cornerstone therapy for MS and will likely continue to be vital.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...